Mycenax and Spera Pharma form ADC manufacturing alliance
Mycenax Biotech (TWO:4726) has formed a strategic partnership with Japan’s Spera Pharma to create a unified pathway for antibody-drug conjugates and other bioconjugates. The alliance merges Mycenax’s biologics manufacturing expertise with Spera’s chemistry and high-potent aseptic fill-finish services, offering developers an integrated, cost-effective route to market.
The collaboration spans the entire ADC value chain, from linker and payload synthesis through drug substance production, formulation, and sterile fill-finish. The two companies aim to reduce complexity for biopharma firms by eliminating multiple hand-offs, potentially accelerating time-to-market for therapies in oncology and beyond.
Rising demand for ADC capacity
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze